Amgen (NASDAQ: AMGN) Follows Tuesday Q2 Beat With Wednesday August 5 Disclosure That the Company Is Ending Development of AMG 513, an Early-Stage Obesity Candidate; The Discontinuation Allows the MariTide (Maridebart Cafraglutide) Monthly-Injectable Antibody-Peptide Conjugate for Obesity to Remain the Sole Obesity Focus in the Amgen Pipeline; Amgen's Full-Year 2026 Guidance Raised to $38.2-39.4 Billion Revenue (Midpoint $38.8 Billion vs $37.7 Billion Consensus) With Continued Analyst Focus on the Upcoming MariTide, Olpasiran, and Xaluritamig Data Readouts as Key Drivers of Growth Beyond the Established Repatha, EVENITY, and TEZSPIRE Franchises
Amgen (NASDAQ: AMGN) followed its Tuesday August 4, 2026 Q2 earnings beat with the Wednesday August 5 disclosure that the company is ending development of AMG 513, an early-stage obesity candidate. The discontinuation allows MariTide (maridebart cafraglutide, the monthly-injectable antibody-peptide conjugate targeting GLP-1 and GIP receptors) to remain the sole obesity focus in the Amgen pipeline as it advances through the Phase 3 MARITIME program (MARITIME-1 obesity, MARITIME-CV cardiovascular outcomes, MARITIME-HF heart failure). Amgen's Q2 2026 revenue reached $10.05 billion (+10% YoY) with adjusted EPS of $6.29 (+4% YoY, beating the $5.62 consensus). Full-year 2026 guidance was raised to $38.2-39.4 billion revenue (midpoint $38.8 billion versus $37.7 billion consensus) with adjusted EPS guidance of $22.30-23.50. Management emphasized the potential of upcoming data readouts for MariTide, Olpasiran (Lp(a)-lowering siRNA), and Xaluritamig (prostate cancer BiTE) to drive future growth beyond the established Repatha (PCSK9), EVENITY (osteoporosis), TEZSPIRE (severe asthma), and UPLIZNA (neuromyelitis optica) franchises. AMG 513 mechanism and stage details were not extensively disclosed, but the discontinuation signals disciplined pipeline management focused on the higher-conviction MariTide bet.